Aptar Pharma Enters Collaboration with CHI for Quattrii DPI Platform

• Aptar Pharma announces exclusive collaboration with CHI for Quattrii DPI platform commercialisation.

• The agreement will provide Aptar’s support for Quattrii manufacturing and customer contact.

Aptar Pharma has announced an exclusive collaboration with Cambridge Healthcare Innovations (CHI) to lead the commercialisation of the Quattrii Dry Powder Inhaler (DPI) platform. Through this agreement, Aptar Pharma will serve as the primary contact for customers and prepare the platform for commercial manufacturing, leveraging its pharmaceutical services to support Quattrii’s growth.

The Quattrii DPI technology is designed to deliver medium to high payloads of formulation directly to the lungs. A notable feature of the platform is its blister piercing array, which creates specific airflow to help classify the powder: larger carrier particles are retained, allowing patients to inhale only the active ingredient. The array can also be adjusted to deliver the entire powder load. This adaptability aims to improve deep lung deposition and reduce cough risk.

Howard Burnett, Vice President of Aptar Pharma’s Global Pulmonary Category, commented, “The CHI team brings deep knowledge, experience and innovation to the dry powder inhaler landscape. Aptar Pharma is very pleased to offer the Quattrii technology in partnership with CHI’s expertise. This enables us to provide full support from our portfolio of services to all drug developers, from formulation development to patient onboarding.”

David Harris, co-founder and CEO of CHI, noted that this partnership will give Aptar’s pharmaceutical clients access to a next-generation DPI platform that supports high doses of low-potency molecules, expanding treatment options across various conditions.